Original research articleEffect of glimepiride on the skeletal system of ovariectomized and non-ovariectomized rats
Introduction
Glimepiride is an oral antidiabetic drug, a third-generation sulfonylurea derivative, used in the treatment of type 2 diabetes mellitus. Hormonal and metabolic disturbances, noted in the course of type 2 diabetes mellitus, result in lesions that have the character of neuropathies, nephropathies, micro- and macroangiopathies, or retinopathies; they also predispose to more frequent occurrence of osteoporotic bone fractures [1], [2], [3], [4], [5]. Diabetes mellitus type 2 develops most often in people who are aged between 40 and 50 years, when, simultaneously, resorption prevails in the bone remodeling processes, which leads to the development of osteoporosis.
It has been demonstrated so far that bone tissue condition in patients suffering from type 2 diabetes mellitus is the result of factors that affect bone condition in a protective manner (body mass increase, hyperinsulinemia), factors that intensify bone resorption (insulin resistance, hyperglycemia, advanced glycation end products), as well as the influence of the pharmacological therapy [1], [6]. It is known that some oral antidiabetic drugs (in particular the derivatives of thiazolidinedione) may cause bone loss, and reduced bone mineral density, which is why they cannot be used safely in the treatment of diabetes, especially in postmenopausal women [7], [8].
The influence of glimepiride on bone tissue is poorly understood. So far, the experiments that have been conducted on cell cultures demonstrate beneficial effect of this drug on proliferation and differentiation of osteoblasts [9], [10].
The aim of this study was to examine the influence of glimepiride on the skeletal system in ovariectomized rats with estrogen deficiency, and in non-ovariectomized rats, with physiological estrogen levels.
Section snippets
Material and methods
The study concerning the influence of glimepiride on bone tissue was conducted, with the approval of Local Ethics Commission in Katowice on 40 sexually mature female Wistar rats, with an initial body weight of 200–250 g. In case of 20 female rats, the procedure of bilateral ovariectomy was conducted under general anesthesia with ketamine (Bioketan, Vetoquinol Biowet) at a dose of 35 mg/kg and xylazine (Rometar, Spofa) at a dose of 5 mg/kg, administered intraperitoneally (ip). Seven days after the
Body mass gain, uterus and thymus mass
In the group of bilaterally ovariectomized (OVX) rats, a statistically significant increase in the body mass, by 246.9%, reduction in the uterus mass, by 74.6%, as well as increase in the thymus mass, by 81.2%, in comparison with the results obtained in the group of non-ovariectomized control animals (NOVX) has been demonstrated (Table 1). Those results indicate the occurrence of estrogen deficiency in ovariectomized rats, and confirm the correct performance of the bilateral ovariectomy
Discussion
Bilateral ovariectomy causes similar changes in the rat skeletal system to those observed in postmenopausal women. Therefore bilateral ovariectomy in female rats has been accepted as an experimental model of postmenopausal osteoporosis, commonly used in pharmacological studies [17], [18], [19].
The results of this study confirmed that bilateral ovariectomy caused estrogen deficiency in the organism of animals, which was manifested by a significant reduction in the mass of the uterus/body mass
Conflict of interest
There is no current, or potential conflict of interest.
Funding
The study was supported by Medical University of Silesia in Katowice – grant KNW-1-044/D/1/0.
References (30)
- et al.
Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase/Akt pathway
Metabolism
(2010) - et al.
Extrapancreatic roles of glimepiride on osteoblasts from rat manibular bone in vitro: regulation of cytodifferentiation through PI3-kinases/Akt signalling pathway
Arch Oral Biol
(2011) - et al.
Proton pump (H+/K+-ATPase) inhibitors weaken the protective effect of alendronate on bone mechanical properties in estrogen-deficient rats
Pharmacol Rep
(2012) - et al.
Basic biomechanical measurements of bone: a tutorial
Bone
(1993) The ovariectomized rat model of postmenopausal bone loss
Bone Miner
(1991)- et al.
KATP channels in mesenchymal stromal stem cells: strong up-regulation of Kir6.2 subunits upon osteogenic differentiation
Tissue Cell
(2011) The role of glimepiride in the effective management of Type 2 diabetes
J Diabetes Complications
(2004)- et al.
Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do?
Patient Prefer Adherence
(2012) Zmiany kostne w cukrzycy
Nowa Klin
(2007)Report of a WHO consultation: definition, diagnosis and classification of diabetes mellitus and its complications
(1999)
Treating diabetes today: a matter of selectivity of sulphonylureas
Diabetes Obes Metab
Diabetes and skeletal health
J Diabetes
Czy cukrzyca typu 2 predysponuje do osteoporotycznych złamań kości?
Endokrynol Pol
Skeletal consequences of thiazolidinedione therapy
Osteoporos Int
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes
J Clin Endocrinol Metab
Cited by (26)
Solid-liquid equilibrium, thermodynamic modelling and the solvent effect of glimepiride in mono-solvents and binary mixed solvents
2022, Journal of Molecular LiquidsCitation Excerpt :Glimepiride is the third generation of sulfonylurea long-acting anti glycemic drugs. It can control blood sugar level well in patients with type II diabetes [1]. Compared with gliclazide and glipizide, glimepiride has few cardiovascular side effects [2].
Impact of glucose-lowering medications on bone health in diabetes
2020, Diabetes Mellitus: Impact on Bone, Dental and Musculoskeletal HealthDiabetes, diabetic medications, and risk of fracture
2020, Marcus and Feldman’s OsteoporosisEffect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies
2017, Pharmacological ReportsCitation Excerpt :Furthermore, Ma and colleagues also suggested that PI3 K/Akt/eNOS signalling pathway plays a vital role in glimepiride-induced osteoblast differentiation in response to high glucose microenvironment [113]. In addition, glimepiride in OVX rats inhibited the skeletal changes induced by estrogen deficiency and increases bone formation [114]. In the Japanese population, sulphonylurea treatment significantly decreased the level of urinary N-terminal Cross-linked telopeptide of type I collagen (uNTX) in postmenopausal women when compared with untreated groups (48.3 ± 21.1 vs. 57.0 ± 36.2, p = 0.038) [115].
Atypical Femoral Fractures—Ongoing and History of Bone-Specific Therapy, Concomitant Diseases, Medications, and Survival
2016, Journal of Clinical DensitometryCitation Excerpt :More than 4 times as many AFF patients had an ongoing antidiabetic therapy with sulfonylurea. Studies evaluating a potential association between these antidiabetics and fracture risk are sparse and yield inconsistent results (34,35). The proportion of patients with diagnosed hypothyroidism was higher in the AFF group, suggesting a low bone turnover (36).